Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and non-invasive measures of enthesitis

  • STATUS
    Recruiting
  • participants needed
    40
Send
Updated on 19 February 2024

Summary

The purpose of this study is to determine how psoriatic nail disease is affected by secukinumab. Secukinumab (Cosentyx®) is a prescription medicine that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis in adults. While secukinumab has already been approved to treat psoriasis, the goal of this study is to look more closely at how it affects specific measures of psoriatic nail disease including imaging and patient reported measurements. Secukinumab is known as a biologic, and works by blocking the activity of a specific protein in the immune system, interleukin-17A, which is believed to be involved in psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Secukinumab will be given at the currently approved dose for psoriasis which is 300 mg subcutaneously (under the skin) every 4 weeks with a loading regimen of 300 mg at a first baseline visit and then at Weeks 1, 2, 3, and 4.

Description


FAQ


Details
Condition Nail Psoriasis
Age 18years - 99years
Clinical Study IdentifierTX6464
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.